Evidence map›Paper›PMID 32536546›Full record

ArticleVaccine2020

HPV vaccine coverage and acceptability among a national sample of sexual minority women ages 18-45.

Paul L Reiter, Gabriela Bustamante, Annie-Laurie McRee

Abstract read
In one paragraph

Article in Vaccine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Facilitators and Barriers of HPV Vaccine Acceptance, Initiation, and Completion among LGBTQ Community in the U.S.: A Systematic Review.International journal of sexual health : official journal of the World Association for Sexual Health · 2022
    Article
  11. Article
  12. Social capital interventions for human papillomavirus (HPV) immunization and cervical cancer screening: A rapid review.Canada communicable disease report = Releve des maladies transmissibles au Canada
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Paul L ReiterCollege of Public Health, The Ohio State University, Columbus, OH, USA; Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA. Electronic address: reiter.36@osu.edu.
Gabriela BustamanteProgram in Health Disparities Research, University of Minnesota, Minneapolis, MN, USA; School of Medicine, Universidad San Francisco de Quito, Quito, Ecuador.
Annie-Laurie McReeDivision of General Pediatrics and Adolescent Health, University of Minnesota Medical School, Minneapolis, MN, USA.

Funding

Cancer Related Health Disparities Training ProgramT32CA163184 · NCI · UNIVERSITY OF MINNESOTA · PI MICHELE L ALLEN, Irina Stepanov · 2016 to 2026
$3.4M
NCI NIH HHS T32 CA163184
6 · The paper itself

Abstract

backgroundSexual minority women (lesbian, bisexual, and other women who have sex with women) are at risk for human papillomavirus (HPV) infection and HPV-related disease, demonstrating the importance of HPV vaccination for these women.

methodsWe conducted an online survey of sexual minority women ages 18-45 from the United States (n = 505) in October 2019, about two months after HPV vaccine recommendations were expanded to include ages 27-45. Multivariable Poisson regression identified correlates of HPV vaccine initiation (i.e., receipt of at least one HPV vaccine dose).

resultsOverall, 65% of participants ages 18-26 and 33% of participants ages 27-45 had initiated the HPV vaccine series. Among participants ages 18-26, initiation was more common among those who had received a healthcare provider recommendation (RR = 2.19, 95% CI: 1.64-2.93) or had disclosed their sexual orientation to their primary healthcare provider (RR = 1.33, 95% CI: 1.07-1.65). Among initiators ages 27-45, a large majority (89%) reported receiving their first dose before turning age 27. Initiation was more common among participants ages 27-45 who had received a healthcare provider recommendation (RR = 3.23, 95% CI: 2.31-4.53) or who reported greater perceived social support for HPV vaccination (RR = 1.22, 95% CI: 1.05-1.40). Several reasons for not yet getting HPV vaccine differed by age group (ages 18-26 vs. ages 27-45; all p < 0.05).

conclusionsMany sexual minority women, particularly those ages 27-45, remain unvaccinated against HPV. Findings provide early insight into HPV vaccine coverage among adult women and highlight key leverage points for increasing vaccination among this population.

Indexed as

Papillomavirus InfectionsPapillomavirus VaccinesSexual and Gender MinoritiesAdolescentAdultFemaleHealth Knowledge, Attitudes, PracticeHumansMaleMiddle AgedUnited StatesVaccinationYoung AdultPapillomavirus VaccinesHPV vaccineHuman papillomavirusSexual orientationWomen

Identifiers

PMID32536546
PMCPMC7323872

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.